Generic Oseltamivir (Tamiflu)
Influenza
Key Facts
About Natco Pharma
Natco Pharma's mission is to deliver affordable, high-quality medicines for complex and life-threatening conditions, primarily through the development and manufacture of generic drugs and active pharmaceutical ingredients (APIs). The company has achieved notable success, particularly with its pioneering launch of a generic version of the hepatitis C drug sofosbuvir in India, which dramatically reduced treatment costs and expanded access. Its strategy centers on vertical integration, targeting therapeutic areas with high unmet need and significant cost burdens, and leveraging its expertise in reverse engineering and complex formulation to secure first-to-file and first-to-market opportunities globally.
View full company profileTherapeutic Areas
Other Influenza Drugs
| Drug | Company | Phase |
|---|---|---|
| PanCytoVir™ (oral probenecid) | TrippBio | IND Submitted |
| Influenza Antibodies | new/era/mabs | Research/Pre-clinical |
| Influenza Countermeasure Program | DynPort Vaccines | Not Specified |
| Influenza Vaccine | Medigen | Preclinical |
| Nasal Influenza Vaccine | Abera Bioscience | Pre-clinical |
| Zapnometinib (ATR-002) | Atriva Therapeutics | Phase 2 |
| EV25 | Eradivir | Pre-clinical |
| Not Specified | New Amsterdam Sciences | Pre-clinical |
| Influenza Program | Arisan Therapeutics | Preclinical |
| Universal Influenza Vaccine | Orlance | Pre-IND |
| Enhanced Seasonal Influenza Vaccine | Orlance | Research |
| Baloxavir marboxil (Xofluza®) | Shionogi | Marketed |